Compare Stocks

→ World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTC Benitec Biopharma	$6.80 +1.2%	$4.99	$1.86 ▼ $9.01	$17.61M	1.03	66,744 shs	4,015 shs
DFFN Diffusion Pharmaceuticals		$4.64	$2.76 ▼ $7.40	$8.98M	1.78	10,937 shs	351,000 shs
QBIO Q BioMed	$0.00	$0.00	$0.00 ▼ $0.02	$29K	1.72	538 shs	N/A
SNNA Sienna Biopharmaceuticals	$0.14	$0.14	$0.06 ▼ $3.80	$4.20M	2.67	1.87 million shs	13.32 million shs
TRIL Trillium Therapeutics	$18.44	$18.12	$5.80 ▼ $20.96	$1.94B	2.08	1.87 million shs	8 shs

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTC Benitec Biopharma	-2.04%	+40.00%	+33.33%	+128.57%	+79.76%
DFFN Diffusion Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-22.81%
QBIO Q BioMed	0.00%	+100.00%	-33.33%	-71.43%	-98.58%
SNNA Sienna Biopharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
TRIL Trillium Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Mysterious Gold Leverage Just Announced (Ad)

World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.

Find out what it is and see how you can get in with just a few dollars.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BNTC Benitec Biopharma	1.5696 of 5 stars	3.5	3.0	0.0	0.0	2.3	0.8	0.0
DFFN Diffusion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
QBIO Q BioMed	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SNNA Sienna Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TRIL Trillium Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTC Benitec Biopharma	3.00	Buy	$16.00	135.29% Upside
DFFN Diffusion Pharmaceuticals	N/A	N/A	N/A	N/A
QBIO Q BioMed	N/A	N/A	N/A	N/A
SNNA Sienna Biopharmaceuticals	N/A	N/A	N/A	N/A
TRIL Trillium Therapeutics	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest TRIL, SNNA, DFFN, BNTC, and QBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
4/22/2024	BNTC Benitec Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$10.00 ➝ $16.00
2/15/2024	BNTC Benitec Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$8.00 ➝ $10.00

(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTC Benitec Biopharma	$80K	220.15	N/A	N/A	$0.12 per share	56.67
DFFN Diffusion Pharmaceuticals	N/A	N/A	N/A	N/A	$6.97 per share	N/A
QBIO Q BioMed	$280K	0.10	N/A	N/A	($0.11) per share	0.00
SNNA Sienna Biopharmaceuticals	N/A	N/A	N/A	N/A	$1.27 per share	N/A
TRIL Trillium Therapeutics	$150K	12,907.39	N/A	N/A	$2.56 per share	7.20

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTC Benitec Biopharma	-$19.56M	N/A	0.00	∞	N/A	N/A	-204.34%	-142.81%	5/20/2024 (Estimated)
DFFN Diffusion Pharmaceuticals	-$15.59M	N/A	0.00	N/A	N/A	N/A	-69.96%	-62.98%	N/A
QBIO Q BioMed	-$2.05M	-$0.03	N/A	∞	N/A	N/A	N/A	N/A	5/26/2024 (Estimated)
SNNA Sienna Biopharmaceuticals	-$73.47M	-$3.59	N/A	N/A	N/A	N/A	-177.36%	-52.22%	N/A
TRIL Trillium Therapeutics	-$59.35M	$0.62	29.74	N/A	N/A	N/A	-23.31%	-18.66%	N/A

Latest TRIL, SNNA, DFFN, BNTC, and QBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/13/2024	Q2 2024	BNTC Benitec Biopharma	N/A	-$2.64	-$2.64	-$2.64	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
DFFN Diffusion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
QBIO Q BioMed	N/A	N/A	N/A	N/A	N/A
SNNA Sienna Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
TRIL Trillium Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTC Benitec Biopharma	0.01	3.62	3.62
DFFN Diffusion Pharmaceuticals	N/A	10.71	10.71
QBIO Q BioMed	N/A	N/A	N/A
SNNA Sienna Biopharmaceuticals	N/A	15.27	15.27
TRIL Trillium Therapeutics	N/A	19.82	19.82

Ownership

Institutional Ownership

Company	Institutional Ownership
BNTC Benitec Biopharma	52.19%
DFFN Diffusion Pharmaceuticals	9.95%
QBIO Q BioMed	N/A
SNNA Sienna Biopharmaceuticals	17.36%
TRIL Trillium Therapeutics	87.15%

Insider Ownership

Company	Insider Ownership
BNTC Benitec Biopharma	4.30%
DFFN Diffusion Pharmaceuticals	1.80%
QBIO Q BioMed	28.20%
SNNA Sienna Biopharmaceuticals	27.20%
TRIL Trillium Therapeutics	9.10%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTC Benitec Biopharma	18	2.59 million	2.48 million	No Data
DFFN Diffusion Pharmaceuticals	13	2.04 million	2.00 million	Not Optionable
QBIO Q BioMed	3	145.10 million	104.18 million	Not Optionable
SNNA Sienna Biopharmaceuticals	39	30.91 million	N/A	Not Optionable
TRIL Trillium Therapeutics	33	105.00 million	95.44 million	Optionable

TRIL, SNNA, DFFN, BNTC, and QBIO Headlines

Source	Headline
	Cachet Bicycle shakes off COVID baytoday.ca - February 25 at 12:23 PM
	Rejuvenate your look with a trip to Fourth Avenue Medical Aesthetics chch.com - January 30 at 5:32 PM
	TTI apprehends motorists for illegal removal of clamps, hunt for four others underway bulawayo24.com - January 30 at 5:32 PM
	BridgeBio raises $1.25bn, and other biotech financings pharmaphorum.com - January 19 at 7:18 AM
	Ratio Therapeutics Raises $50M in Series B Financing precisionmedicineonline.com - January 17 at 1:39 PM
	Leiomyosarcoma Drug Pipeline Report 2023 - ResearchAndMarkets.com businesswire.com - November 10 at 1:22 PM
	Mirati Therapeutics Stock (NASDAQ:MRTX), Analyst Ratings, Price Targets, Predictions benzinga.com - November 8 at 1:30 AM
	The Global T-Cell therapy Market size is expected to reach $9.2 billion by 2030, rising at a market growth of 17.5% CAGR during the forecast period uk.finance.yahoo.com - July 31 at 9:03 AM
	Ratio Therapeutics unveils new research and development facility biopharma-reporter.com - May 15 at 10:33 AM
	WHO Red Flags Punjab-Made Cough Syrup In Fresh Alert: 'Can Cause Even Death' msn.com - April 26 at 12:18 AM
	Leukemia Therapeutics Global Market Report 2023 uk.finance.yahoo.com - April 4 at 10:35 AM
	Ratio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with Merck finance.yahoo.com - March 28 at 9:12 AM
	Trillium House, an affordable housing project in Warrenton, close to completion dailyastorian.com - January 10 at 12:26 AM
	FDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular Carcinoma nz.finance.yahoo.com - October 19 at 9:39 AM
	Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment seekingalpha.com - September 14 at 9:48 AM
	Zentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of Directors nz.finance.yahoo.com - September 12 at 7:55 AM
	Pfizer: Deal For Global Blood Therapeutics Carries Risk - More M&A Is Needed seekingalpha.com - August 17 at 11:07 AM
	TTI reviews parking model chronicle.co.zw - August 10 at 10:41 PM
	TTI working round the clock to configure its systems chronicle.co.zw - August 10 at 10:41 PM
	Pfizer in advanced talks to buy firm making sickle cell drugs pmnewsnigeria.com - August 7 at 3:57 AM
	10 Psychedelics CEOs To Pay Attention To In 2022 markets.businessinsider.com - June 22 at 10:08 AM
	Highlights from ASCO Annual Meeting 2022 healio.com - June 15 at 1:37 PM
	Chlormethine gel may be more effective than ointment for mycosis fungoides healio.com - May 27 at 4:34 PM
	Pfizer and Moderna created life-saving vaccines. So why are their stocks crumbling? edition.cnn.com - May 20 at 2:06 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Benitec Biopharma

NASDAQ:BNTC

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Diffusion Pharmaceuticals

NASDAQ:DFFN

Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company was founded in 2001 and is based in Charlottesville, Virginia.

Q BioMed

OTCMKTS:QBIO

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.

Sienna Biopharmaceuticals

NASDAQ:SNNA

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery, clinical development, and commercialization of aesthetics and medical dermatology. Its products include Topical by Design platform for patients with inflammatory skin diseases and other dermatologic and aesthetic conditions through SNA-120, SNA-125, and SNA-001. The company was founded by Todd Harris and Frederick C. Beddingfield III on July 27, 2010 and is headquartered in Westlake Village, CA.

Trillium Therapeutics

NASDAQ:TRIL

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial